-
Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.
Toxicology and applied pharmacology 20131201
-
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120910
-
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.
Current drug metabolism 20120901
-
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120801
-
HER2 testing in patients with breast cancer.
BMJ (Clinical research ed.) 20120611
-
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.
Investigational new drugs 20120601
-
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Journal of clinical pharmacology 20120501
-
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
Cancer chemotherapy and pharmacology 20120501
-
Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20120301
-
An isolable acyclic hemiacetal of ansamitocin P-3.
Magnetic resonance in chemistry : MRC 20120301
-
Biosynthesis of 3,5-AHBA-derived natural products.
Natural product reports 20120201
-
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
Nature biotechnology 20120122
-
The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library.
Angewandte Chemie (International ed. in English) 20120116
-
Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3.
Chemistry (Weinheim an der Bergstrasse, Germany) 20120116
-
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology 20120101
-
Dual carbamoylations on the polyketide and glycosyl moiety by asm21 result in extended ansamitocin biosynthesis.
Chemistry & biology 20111223
-
Enhanced production of ansamitocin P-3 by addition of Mg2+ in fermentation of Actinosynnema pretiosum.
Bioresource technology 20111101
-
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review.
Current opinion in oncology 20111101
-
Enthusiasm for antibody-drug conjugates.
Journal of the National Cancer Institute 20111019
-
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 20111015
-
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 20111015
-
A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions.
Chemical communications (Cambridge, England) 20111014
-
Modeling the effects of drug binding on the dynamic instability of microtubules.
Physical biology 20111001
-
Antibody-DM1 conjugates as cancer therapeutics.
Cancer letters 20110828
-
N-methylation of the amide bond by methyltransferase asm10 in ansamitocin biosynthesis.
Chembiochem : a European journal of chemical biology 20110725
-
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
Breast cancer research and treatment 20110701
-
Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells.
Disease models & mechanisms 20110701
-
Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates.
Journal of medicinal chemistry 20110526
-
Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism.
Bioconjugate chemistry 20110420
-
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.
Bioconjugate chemistry 20110420
-
The microtubule as a breast cancer target.
Breast cancer (Tokyo, Japan) 20110401
-
Mutational biosynthesis of ansamitocin antibiotics: a diversity-oriented approach to exploit biosynthetic flexibility.
Chembiochem : a European journal of chemical biology 20110307
-
Megakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division.
Cytoskeleton (Hoboken, N.J.) 20110301
-
Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110201
-
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110201
-
Enhanced production of ansamitocin P-3 by addition of isobutanol in fermentation of Actinosynnema pretiosum.
Bioresource technology 20110101
-
Can cancer clinical trials be fixed?
Nature biotechnology 20110101
-
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Breast cancer research : BCR 20110101
-
World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.
mAbs 20110101
-
[Antibody-drug conjugate--a new age for personalized cancer treatment].
Chimia 20110101
-
Cyclization of synthetic seco-proansamitocins to ansamitocin macrolactams by Actinosynnema pretiosum as biocatalyst.
Chembiochem : a European journal of chemical biology 20101210
-
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 20101001
-
Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.
Molecular cancer therapeutics 20101001
-
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.
Molecular cancer therapeutics 20101001
-
Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes.
Bioconjugate chemistry 20100915
-
Biological considerations and clinical applications of new HER2-targeted agents.
Expert review of anticancer therapy 20100901
-
A new antitumour ansamitocin from Actinosynnema pretiosum.
Natural product research 20100701
-
[Current impact of natural products in the discovery of anticancer drugs].
Annales pharmaceutiques francaises 20100701
-
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100601
-
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice.
Journal of pharmacokinetics and pharmacodynamics 20100601
-
Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Current opinion in molecular therapeutics 20100601
-
Preparative isolation and purification of anti-tumor agent ansamitocin P-3 from fermentation broth of Actinosynnema pretiosum using high-performance counter-current chromatography.
Journal of separation science 20100501
-
Antibody-maytansinoid conjugates designed to bypass multidrug resistance.
Cancer research 20100315
-
Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Bioconjugate chemistry 20100101
-
Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors.
Journal of Alzheimer's disease : JAD 20100101
-
[Immunoconjugates, drug-armed antibodies to fight against cancer].
Medecine sciences : M/S 20091201
-
Constitutive overexpression of asm2 and asm39 increases AP-3 production in the actinomycete Actinosynnema pretiosum.
Journal of industrial microbiology & biotechnology 20091101
-
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.
Molecular cancer therapeutics 20091001
-
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
-
Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
-
Formal total synthesis of N-methylmaysenine.
Organic letters 20090416
-
Timing of the Delta(10,12)-Delta(11,13) double bond migration during ansamitocin biosynthesis in Actinosynnema pretiosum.
Journal of the American Chemical Society 20090325
-
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.
Cancer research 20090315
-
P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.
BMC cancer 20090101
-
Antibody-maytansinoid conjugates for the treatment of myeloma.
mAbs 20090101
-
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Cancer research 20081115
-
Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana.
Bioorganic & medicinal chemistry 20081101
-
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
Cancer chemotherapy and pharmacology 20081001
-
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma.
Oral oncology 20080901
-
Amide N-glycosylation by Asm25, an N-glycosyltransferase of ansamitocins.
Chemistry & biology 20080825
-
Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.
Bioconjugate chemistry 20080801
-
Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.
Clinical cancer research : an official journal of the American Association for Cancer Research 20080715
-
Highly active ansamitocin derivatives: mutasynthesis using an AHBA-blocked mutant.
Chembiochem : a European journal of chemical biology 20080505
-
Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Accounts of chemical research 20080101
-
The ansacarbamitocins: polar ansamitocin derivatives.
Journal of natural products 20071001
-
Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
Cancer research 20070701
-
New amide N-glycosides of ansamitocins identified from Actinosynnema pretiosum.
Archives of pharmacal research 20070601
-
Chemoenzymatic approaches toward dechloroansamitocin P-3.
Organic letters 20070412
-
Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.
International journal of oncology 20070401
-
An integrative expression vector for Actinosynnema pretiosum.
BMC biotechnology 20070101
-
On the biosynthetic origin of methoxymalonyl-acyl carrier protein, the substrate for incorporation of 'glycolate' units into ansamitocin and soraphen A.
Journal of the American Chemical Society 20061108
-
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
Clinical cancer research : an official journal of the American Association for Cancer Research 20061015
-
Determination of the cryptic stereochemistry of the first PKS chain-extension step in ansamitocin biosynthesis by Actinosynnema pretiosum.
Chembiochem : a European journal of chemical biology 20060801
-
Semisynthetic maytansine analogues for the targeted treatment of cancer.
Journal of medicinal chemistry 20060713
-
Combinatorial biosynthesis--potential and problems.
Journal of biotechnology 20060625
-
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
Cancer research 20060415
-
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.
Cancer research 20060315
-
Synthesis of the N-acetylcysteamine thioester of seco-proansamitocin.
Organic letters 20060105
-
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry.
Protein science : a publication of the Protein Society 20050901
-
A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates.
Analytical biochemistry 20050515
-
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
Journal of pharmaceutical sciences 20050401
-
Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry.
Journal of mass spectrometry : JMS 20050301
-
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry.
Rapid communications in mass spectrometry : RCM 20050101
-
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
Blood 20041201
-
Technology evaluation: cantuzumab mertansine, ImmunoGen.
Current opinion in molecular therapeutics 20041201
-
An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics.
Journal of pharmaceutical and biomedical analysis 20041119
-
A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer.
Cancer research 20041101
-
Cytotoxic activity of maytanprine isolated from Maytenus diversifolia in human leukemia K562 cells.
Biological & pharmaceutical bulletin 20040801
-
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Cancer research 20040701
-
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 20040701
-
A novel amide N-glycoside of ansamitocins from Actinosynnema pretiosum.
The Journal of antibiotics 20040501
-
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice.
The Journal of pharmacology and experimental therapeutics 20040301
-
Recent developments in the maytansinoid antitumor agents.
Chemical & pharmaceutical bulletin 20040101
-
The post-polyketide synthase modification steps in the biosynthesis of the antitumor agent ansamitocin by Actinosynnema pretiosum.
Journal of the American Chemical Society 20031126
-
Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
European journal of biochemistry 20030901
-
Occurrence and non-detectability of maytansinoids in individual plants of the genera Maytenus and Putterlickia.
Phytochemistry 20030201
-
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030115
-
Identification of asm19 as an acyltransferase attaching the biologically essential ester side chain of ansamitocins using N-desmethyl-4,5-desepoxymaytansinol, not maytansinol, as its substrate.
Journal of the American Chemical Society 20020612
-
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.
Cancer research 20020501
-
Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual 'glycolate' chain extension unit in ansamitocin biosynthesis.
Journal of the American Chemical Society 20020424
-
Perspectives on anti-HER monoclonal antibodies.
Oncology 20020101
-
Technology evaluation: C242-DM1, ImmunoGen Inc.
Current opinion in molecular therapeutics 20010401
-
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
The Journal of biological chemistry 19901005
-
Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines.
Cancer research 19860101